This site is intended for healthcare professionals
News

Novartis announces Tabrecta first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC.

Read time: 3 mins
Last updated:7th Jun 2021
Published:6th Jun 2021
Novartis announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) .
Condition: NSCLC / MET
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest